Skip to main content
Egyptian Rheumatology and Rehabilitation
Download PDF
  • Original article
  • Open access
  • Published:

Significance of antibodies to ribosomal P proteins in lupus nephritis patients and their relation to disease activity: clinical and laboratory study

Egyptian Rheumatology and Rehabilitation volume 44, pages 130–138 (2017)Cite this article

Abstract

Background

Lupus nephritis (LN) is a prominent feature in systemic lupus erythematosus (SLE), present in 15–30% of patients with lupus at the time of the initial diagnosis and in 30–50% during the disease progression.

Objectives

The aim of this study was to determine the significance of anti-ribosomal P protein (anti-P) antibodies and LN and their relation to disease activity and other SLE manifestations.

Patients and methods

Fifty active LN patients were subjected to full clinical examination (assessment of SLE disease activity using the systemic lupus erythematosus disease activity index and assessment of SLE disease severity using Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index), routine laboratory investigations, anti-dsDNA antibodies, and anti-P antibodies.

Results

Comparison between the data of LN in both groups (anti-P positive/anti-dsDNA negative and anti-P negative) shows that there was a statistically significant difference in age (P=0.042), hypertension (P=0.00), and psychiatric manifestations (P=0.004). On comparison of both groups as regards vasculitis, there was a borderline statistical significance (P=0.050). Comparison of both groups as regards creatinine level or biopsy class V showed a statistically significant difference with a higher percentage in the anti-P positive/anti-dsDNA negative group (P=0.024 and 0.040, respectively).

Conclusion

Anti-P antibody-positive patients have younger ages, lower creatinine level, lower incidence of hypertension, usually class V in renal biopsy, but more susceptible to have psychiatric manifestations compared with anti-P antibody negative patients.

References

  1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med 2008; 358:929–939

    Article  CAS  Google Scholar 

  2. Dooley MA. Clinical and laboratory features of lupus nephritis. In: Wallace DJ, Hahn BH, editors. Dubois’ lupus erythematosus. Vol. 56. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. pp. 1112–1130

    Google Scholar 

  3. Cross J, Jayne D. Diagnosis and treatment of kidney disease. Best Pract Res Clin Rheumatol 2005; 19:785–798

    Article  CAS  Google Scholar 

  4. Hill G, Delahousse M, Nochy D. Anew morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 2000; 58:1160–1173

    Article  CAS  Google Scholar 

  5. Austin H, Boumbas D, Vaughan E., Balows J. Predicting renal outcomes in severe lupus nephritis: contribution of clinical & histologic data. Kidney Int 1994; 45:544–550

    Article  Google Scholar 

  6. Chi Chui M. Biomarkers for lupus nephritis: a critical appraisal. J Biomed Biotechnol 2010; 10:1155–1166

    Google Scholar 

  7. Carmona-FernandesD,Santos MJ, Canhão H, FonsecaJE.Anti-ribosomalP protein IgG autoantibodies in patients with systemic lupus erythematosus: diagnostic performance and clinical profile. BMC Med 2013; 11:98

    Article  CAS  Google Scholar 

  8. Sato H, Onozuka M, Hagiya A, Hoshino S, Narita I, Uchiumi T. Characterization of anti-P monoclonal antibodies directed against the ribosomal protein–RNA complex antigen and produced using Murphy Roths large autoimmune-prone mice: Clin Exp Immunol 2015; 179:236–244

    CAS  PubMed  PubMed Central  Google Scholar 

  9. Toubia E, Shoenfeld Y. Clinical and biological apects of anti-P-ribosomal protein autoantibodies. Autoimmun Rev 2007; 6:119–125

    Article  Google Scholar 

  10. Kiss E, Shoenfeld Y. Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus? Clin Rev Allergy Immunol 2007; 32:37–46

    Article  CAS  Google Scholar 

  11. Reichlin M, Wolfson-Reichlin M. Evidence for the participation of anti-ribosomal P antibodies in lupus nephritis. Arthritis Rheum 1999; 42:2728–2729

    Article  CAS  Google Scholar 

  12. Gerli R, Caponi L, Tincani A, Scorza R, Sabbadini MG, Danieli MG, et al. Clinical and serological associations of ribosomal P autoantibodies in systemic lupus erythematosus: prospective evaluation in a large cohort of Italian patients. Rheumatology (Oxford) 2002; 41:1357–1366

    Article  CAS  Google Scholar 

  13. Haddouk S, Marzouk S, Jallouli M, Fourati H, Frigui M, Hmida Y, et al. Clinical and diagnostic value of ribosomal P autoantibodies in systemic lupus erythematosus. Rheumatology 2009; 48:953–954

    Article  CAS  Google Scholar 

  14. Andrade de Macedo P, Borba EF, Viana VST, Leon EP, Testagrossa LA, Barros RT, et al. Antibodies to ribosomal P proteins in lupus nephritis: a surrogate marker for a better renal survival? Autoimmun Rev 2011; 10:126–130

    Article  CAS  Google Scholar 

  15. Sato T, Uchiumi T, Ozawa T. Autoantibodies against ribosomal proteins found with high fequency in patients with systemic lupus erythematosus with active disease. J Rheumatol 1991; 18:1681–1684

    CAS  PubMed  Google Scholar 

  16. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64:2677–2686

    Article  Google Scholar 

  17. Gladman D, Ibanez D, Urowitz M. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29:288–291

    Google Scholar 

  18. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39:363–369

    Article  CAS  Google Scholar 

  19. de Bruijn MH, Fey GH. Human complement component C3: cDNA coding sequence and derived primary structure. Proc Natl Acad Sci U S A 1985; 82:708–712

    Article  Google Scholar 

  20. Aitcheston C, Tan C. Antinuclear antibody in scientific basis of rheumatology. Panayi GS, editor. Melbourne and New York: Churchill Livingstone Edinburgh London; 1982. p. 87

    Google Scholar 

  21. Okamura M, Kanayama Y,Amastu K, Negoro N, Kohda S, Takeda T, Inoue T. Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis 1993; 52:14–20

    Article  CAS  Google Scholar 

  22. do Nascimento AP, Viana Vdos S, Testagrossa Lde A, Leon EP, Borba EF, Barros RT, et al. Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulo-nephritis. Arthritis Rheum 2006; 54:1568–1572

    Article  Google Scholar 

  23. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulo-nephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 2004; 15:241–250

    Article  Google Scholar 

  24. López-Longo FJ, González Fernández CM, Rodríguez Mahou M, Grau Simo R, Monteagudo Saez I, Meno Garcia AC, et al. Clinical expression of systemic lupus erythematosus with anti-U1-RNP and anti-Sm antibodies. Rev Clin Esp 1997; 197:329–335

    PubMed  Google Scholar 

  25. Reichlin M, Broyles TF, Hubscher O, James J, Lehman TA, Palermo R, et al. Prevalence of autoantibodies to ribosomal P proteins in juvenile-onset systemic lupus erythematosus compared with the adult disease. Arthritis Rheum 1999; 42:69–75

    Article  CAS  Google Scholar 

  26. Tzioufas AG, Tzortzakis NG, Panou-Pomonis E, Boki KA, Sakarellos-Daitsiotis M, Sakarellos C, Moutsopoulos HM. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients with active central nervous system involvement. Ann Rheum Dis 2000; 59:99–104

    Article  CAS  Google Scholar 

  27. Barkhudarova F, Dähnrich C, Rosemann A, Schneider U, Stöcker W, Burmester G-R, et al. Diagnostic value and clinical laboratory associations of antibodies against recombinant ribosomal P0, P1 and P2 proteins and their native heterocomplex in a Caucasian cohort with systemic lupus erythematosus. Arthritis Res Ther 2011; 13:R20

    Article  Google Scholar 

  28. Bonfa E, Golombe SJ, Kaufman LD, Skelly S, Weissbach H, Brot N, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987; 317:265–271

    Article  CAS  Google Scholar 

  29. Schneebaum AB, Singleton JP, West SG, Blodgett JK, Allen LG, Cheronis JC, et al. Association of psychiatric manifestations with antibodies to ribosomal P protein in systemic lupus erythematosus. Am J Med 1991; 90:54–62

    Article  CAS  Google Scholar 

  30. Teh L, Isenberg D. Anti-ribosomal P protein antibodies in systemic lupus erythematosus. A reappraisal. Arthritis Rheum 1994; 37:307–308

    Article  CAS  Google Scholar 

  31. Iverson G. Are antibodies to ribosomal P proteins a clinically useful predictor of neuropsychiatric manifestations in patients with systemic lupus erythematosus? Lupus 1996; 5:634–641

    Article  CAS  Google Scholar 

  32. Shi ZR, Cao CX, Tan GZ, Wang L. The association of serum anti-ribosomal P antibody with clinical and serological disorders in systemic lupus erythematosus: a systematic review and meta-analysis. Lupus 2015; 24:588–596

    Article  CAS  Google Scholar 

  33. Mathy JP, Baum R, Toh BH. Autoantibody to ribosomes and systemic lupus erythematosus. Clin Exp Immunol 1980; 41:73–80

    CAS  PubMed  PubMed Central  Google Scholar 

  34. West SG, Wener MH, Kotzin BL. Neuropsychiatric lupus erythematosus: a 10 yr prospective study on the value of diagnostic tests. Am J Med 1995; 99:153–163

    Article  CAS  Google Scholar 

  35. Caponi L, Pegoraro S, Di Bartolo V, Rovero P, Revoltella R, Bombardieri S. Auto-antibodies directed against ribosomal P proteins: use of a multiple antigen peptide as the coating agent in ELISA. J Immunol Meth 1995; 179:193–202

    Article  CAS  Google Scholar 

  36. Shinjo SK, Bonfá E. Cutaneous vasculitis in systemic lupus erythematosus: association with anti-ribosomal P protein antibody and Raynaud phenomenon. Clin Rheumatol 2011; 30:173–177

    Article  Google Scholar 

  37. Mahler M, Kessenbrock K, Szmyrka M, Takasaki Y, Garcia-De La Torre I, Shoenfeld Y, et al. International multicenter evaluation of autoantibodies to ribosomal P proteins. Clin Vaccine Immunol 2006; 13:77–83

    Article  CAS  Google Scholar 

  38. Bertolaccini M, Murru V, Khamashta M. Lack of association of antibodies to ribosomal P proteins with lupus membranous glomerulonephritis: comment on the article by do Nascimento et al. Arthritis Rheum 2006; 54:4025–4026

    Article  CAS  Google Scholar 

  39. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25:1271–1277

    Article  CAS  Google Scholar 

  40. Binder SR, Genovese MC, Merrill JT, Morris RI, Metzger AL. Computer-assisted pattern recognition of autoantibody results. Clin Diagn Lab Immunol 2005; 12:1353–1357

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology and Rehabilitation, Faculty of Medicine, Cairo University, Cairo, Egypt

    Samia H. Fadda

  2. Department of Rheumatology and Rehabilitation, Faculty of Medicine, Beni Suef University, 1 Elgeesh Street, Elsaa Square, Beni Suef, 61511, Egypt

    Mervat I. Abd Elazeem (MD) & Hanaa M. Hasan

  3. Department of Clinical Pathology, Faculty of Medicine, Beni Suef University, Beni Suef, Egypt

    Rabab A. Mohammed

Authors
  1. Samia H. Fadda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mervat I. Abd Elazeem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rabab A. Mohammed
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hanaa M. Hasan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mervat I. Abd Elazeem.

Additional information

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Fadda, S.H., Abd Elazeem, M.I., Mohammed, R.A. et al. Significance of antibodies to ribosomal P proteins in lupus nephritis patients and their relation to disease activity: clinical and laboratory study. Egypt Rheumatol Rehabil 44, 130–138 (2017). https://doi.org/10.4103/err.err_21_17

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/err.err_21_17

Keywords